Prevalence of a Putative Efflux Mechanism among Fluoroquinolone-Resistant Clinical Isolates of Streptococcus pneumoniae
- 1 August 1998
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 42 (8) , 2032-2035
- https://doi.org/10.1128/aac.42.8.2032
Abstract
Twenty-three norfloxacin-selected first-step mutants ofStreptococcus pneumoniae showed low-level fluoroquinolone resistance. Their susceptibility to norfloxacin in the presence or absence of reserpine and known efflux pump substrates was determined by an agar dilution method. Five mutants showed four- to eightfold increases in their susceptibility to norfloxacin in the presence of reserpine and four- to eightfold decreases in their susceptibility to acriflavine and ethidium bromide. This phenotype is suggestive of an efflux mechanism of resistance. A representative of these mutants, 1N27, accumulated significantly less ethidium bromide than the parent strain; reserpine abolished these differences. No changes in the quinolone resistance-determining regions of parC,parE, gyrA, or gyrB were found in this mutant. By our validated agar dilution method, the efflux phenotype was sought in clinical isolates of S. pneumoniae. Of 1,037 clinical isolates examined from the United Kingdom, 273 showed reduced susceptibility to norfloxacin or ciprofloxacin. Of these, 45.4% showed the efflux phenotype. Our findings suggest that an efflux mechanism may be a frequent cause of clinically significant fluoroquinolone resistance in pneumococci.Keywords
This publication has 29 references indexed in Scilit:
- Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 1997
- The effect of reserpine, an inhibitor of multi-drug efflux pumps, on the in-vitro susceptibilities of fluoroquinolone-resistant strains of Streptococcus pneumoniae to norfloxacinJournal of Antimicrobial Chemotherapy, 1997
- In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalisAntimicrobial Agents and Chemotherapy, 1997
- Apparent involvement of a multidrug transporter in the fluoroquinolone resistance of Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 1997
- Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 1997
- Pneumococcal Resistance to β-Lactam Antibiotics: A Global Geographic OverviewMicrobial Drug Resistance, 1995
- Efflux-mediated fluoroquinolone resistance in Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1993
- Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporterAntimicrobial Agents and Chemotherapy, 1993
- Antimicrobial Resistance in Streptococcus pneumoniae: An OverviewClinical Infectious Diseases, 1992
- Efflux-mediated multidrug resistance in Bacillus subtilis: similarities and dissimilarities with the mammalian system.Proceedings of the National Academy of Sciences, 1991